Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 6/20 | 1.00 |
| ▸ | CASP3 | P42574 | 6/20 | 1.00 |
| ▸ | CASP9 | P55211 | 6/20 | 1.00 |
| ▸ | CYCS | P99999 | 6/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401180 | 0.95 | APAF1 (0.91) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4395653 | 0.95 | APAF1 (0.90) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4397286 | 0.94 | APAF1 (0.90) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4398368 | 0.93 | APAF1 (0.87) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4541497 | 0.93 | APAF1 (0.86) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4391634 | 0.93 | APAF1 (0.86) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4396565 | 0.91 | APAF1 (0.83) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4395693 | 0.88 | APAF1 (0.79) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4391987 | 0.87 | APAF1 (0.77) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL4394053 | 0.87 | APAF1 (0.77) | APAF1CASP3CASP9CYCSACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220307028-A1 | COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY | JAAN BIOTHERAPEUTICS, LLC | 2022-09-29 | — | — | US | claimed |
| EP-4048398-A1 | COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY | Jaan Biotherapeutics, LLC (US) | 2022-08-31 | — | — | EP | claimed |
| US-20250251902-A1 | Record Check | SUPERSCOPE TECH INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-12215356-B2 | Methods of preparing a primary cell sample | CELCUITY INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240409946-A1 | MICRORNA TARGETING REGENERATIVE TREATMENTS FOR HEART FAILURE | JAAN BIOTHERAPEUTICS LLC | 2024-12-12 | — | — | US | disclosed |
| CN-114073076-B | Signaling of quantization matrices | 寰发股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023159150-A1 | MICRORNA TARGETING REGENERATIVE TREATMENTS FOR HEART FAILURE | JAAN BIOTHERAPEUTICS LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20230235293-A1 | METHODS OF PREPARING A PRIMARY CELL SAMPLE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11591573-B2 | Methods of preparing a primary cell sample | CELCUITY INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220307028-A1 | COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY | JAAN BIOTHERAPEUTICS, LLC | 2022-09-29 | — | — | US | disclosed |
| EP-4048398-A1 | COMPOSITIONS AND METHODS FOR MITIGATION OF ISCHEMIC REPERFUSION INJURY | Jaan Biotherapeutics, LLC (US) | 2022-08-31 | — | — | EP | disclosed |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3987775-A1 | SIGNALING OF QUANTIZATION MATRICES | HFI Innovation Inc. (TW) | 2022-04-27 | — | — | EP | disclosed |
| US-20220118101-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING INFLAMMATION BY INHIBITING CASPASE-9 | UNIV COLUMBIA (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3982366-A1 | A MARCHING MEMORY, A BIDIRECTIONAL MARCHING MEMORY, A COMPLEX MARCHING MEMORY AND A COMPUTER SYSTEM, WITHOUT THE MEMORY BOTTLENECK | Nakamura, Tadao (JP) | 2022-04-13 | — | — | EP | disclosed |
| CN-114073076-A | Signaling of quantization matrices | 联发科技股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-1963357-B1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | SALVAT LAB SA (ES) | 2009-12-09 | — | — | EP | disclosed |
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | CONSEJO SUPERIOR DE (ES) | 2009-12-03 | — | — | US | disclosed |
| EP-1963357-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | Laboratorios SALVAT, S.A. (ES) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007060524-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | LABORATORIOS SALVAT, S.A. (ES) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298781-A1 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS | BAX, BCL2, CASP3 | APAF1 27/4885CASP3 3/4885CASP9 9/4885 |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | CXCL12, ATP6V1B1, VIP | APAF1 1802/4885CASP3 2442/4885CASP9 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.